Conformis, Inc. to Post Q1 2021 Earnings of ($0.08) Per Share, Oppenheimer Forecasts (NASDAQ:CFMS)

Conformis, Inc. (NASDAQ:CFMS) – Stock analysts at Oppenheimer issued their Q1 2021 EPS estimates for shares of Conformis in a research note issued to investors on Thursday, February 18th. Oppenheimer analyst S. Lichtman forecasts that the medical instruments supplier will post earnings per share of ($0.08) for the quarter. Oppenheimer also issued estimates for Conformis’ Q2 2021 earnings at ($0.05) EPS, Q3 2021 earnings at ($0.04) EPS and Q4 2021 earnings at ($0.03) EPS.

A number of other research firms have also commented on CFMS. Zacks Investment Research lowered Conformis from a “hold” rating to a “sell” rating in a research note on Thursday. Cowen reiterated an “outperform” rating and issued a $2.00 price objective on shares of Conformis in a research note on Sunday, November 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $1.94.

Conformis stock opened at $1.07 on Monday. The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.50 and a current ratio of 1.90. The business’s 50-day simple moving average is $1.09 and its 200-day simple moving average is $0.80. The firm has a market capitalization of $102.23 million, a PE ratio of -3.15 and a beta of 1.63. Conformis has a 52 week low of $0.50 and a 52 week high of $1.49.

In related news, CEO Mark A. Augusti sold 61,025 shares of Conformis stock in a transaction dated Monday, January 4th. The stock was sold at an average price of $0.64, for a total transaction of $39,056.00. Following the sale, the chief executive officer now directly owns 2,280,345 shares of the company’s stock, valued at $1,459,420.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last three months, insiders have sold 75,693 shares of company stock worth $54,641. 3.19% of the stock is owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC grew its position in Conformis by 12.8% during the fourth quarter. Renaissance Technologies LLC now owns 5,882,971 shares of the medical instruments supplier’s stock worth $3,883,000 after buying an additional 668,880 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in Conformis by 126.4% during the third quarter. Squarepoint Ops LLC now owns 403,672 shares of the medical instruments supplier’s stock valued at $338,000 after purchasing an additional 225,364 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Conformis by 17.4% during the third quarter. Acadian Asset Management LLC now owns 354,359 shares of the medical instruments supplier’s stock valued at $296,000 after purchasing an additional 52,524 shares in the last quarter. CAPROCK Group Inc. boosted its holdings in Conformis by 40.0% during the fourth quarter. CAPROCK Group Inc. now owns 280,000 shares of the medical instruments supplier’s stock valued at $185,000 after purchasing an additional 80,000 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in Conformis during the fourth quarter valued at approximately $116,000. 30.24% of the stock is currently owned by institutional investors and hedge funds.

About Conformis

Conformis, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; and iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.

Recommended Story: How is a buy-side analyst different from a sell-side analyst?

Receive News & Ratings for Conformis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conformis and related companies with MarketBeat.com's FREE daily email newsletter.